Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1507-1516

  Tsimberidou, Apostolia Maria ^a   Lewis, Nancy ^b,c   Reid, Tony ^d   Burris, Howard ^e   Urban, Patrick ^f   Tan, Eugene Y ^f   Anand, Suraj ^f   Uehara, Cynthia ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Drug interaction; Midazolam; Omeprazole; Patupilone; Pharmacokinetics; Phase 1; Solid tumors

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; EPOTHILONE B; MIDAZOLAM; OMEPRAZOLE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; OSTEOSARCOMA; OVARY ADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PLEURA CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SKIN MELANOMA; TESTIS CANCER; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING;

EID: 85027921054     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1635-7     Document Type: Article

References (18)

1. (2010) Omeprazole prescribing information. AstraZeneca LP, Wilmington
2. Abrey LE, Wen P, Govindan R, Reimers H, Rigas JR, Robins HI, Allen-Freda E, Gao B, Ko J, Johri A (2008) Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): an open-label phase II study. J Clin Oncol 26:15 s (suppl; abstr 2033)
3. KH Altmann M Wartmann T O'Reilly 2000 Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity Biochim Biophys Acta 1470 M79 M91 10799747 1:CAS:528: DC%2BD3cXivVGlsro%3D
4. Beardsley EK, Saad F, Eigl B, Venner P, Hotte S, Winquist E, Ko YJ, Sridhar SS, Chi KN (2009) A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol 27:15 s (suppl; abstr 5139)
5. DM Bollag PA McQueney J Zhu O Hensens L Koupal J Liesch M Goetz E Lazarides CM Woods 1995 Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action Cancer Res 55 2325 2333 7757983 1:CAS:528:DyaK2MXlvFeqsr0%3D
6. Casado E, Tabernero J, Melichar B, Bridgewater J, Bennouna J, Delord J, Sopala M, Sklenar I, Cheung W, Johri A (2006) Patupilone in chemotherapy- pretreated patients with advanced colorectal cancer (CRC) receiving nutritional support and intensive diarrhea management: a phase I multicenter trial. J Clin Oncol 24:18 s (suppl; 3593)
7. BL Chen Y Chen JH Tu YL Li W Zhang Q Li L Fan ZR Tan DL Hu D Wang LS Wang DS Ouyang HH Zhou 2009 Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms J Clin Pharmacol 49 574 581 19398604 10.1177/0091270009333016 1:CAS:528:DC%2BD1MXlsFWmu7g%3D
8. MS Ching GW Mihaly PW Angus DJ Morgan S Devenish-Meares ND Yeomans RA Smallwood 1991 Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer Br J Clin Pharmacol 31 166 170 2049231 1:STN:280:DyaK3M3msFaisQ%3D%3D
9. M Forster S Kaye A Oza I Sklenar A Johri W Cheung S Zaknoen M Gore 2007 A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178 4184 17634546 10.1158/1078-0432.CCR-06-1653 1:CAS:528:DC%2BD2sXnvVChs7Y%3D (Pubitemid 47105981)
10. JH Kanto 1985 Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia Pharmacotherapy 5 138 155 3161005 1:CAS:528:DyaL2MXltlChsrs%3D (Pubitemid 15066349)
11. RJ Kowalski P Giannakakou E Hamel 1997 Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)) J Biol Chem 272 2534 2541 8999970 10.1074/jbc.272.4.2534 1:CAS:528:DyaK2sXotFCitw%3D%3D (Pubitemid 27058547)
12. T O'Reilly M Wartmann J Brueggen PR Allegrini A Floersheimer M Maira PM McSheehy 2008 Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo Cancer Chemother Pharmacol 62 1045 1054 18301895 10.1007/s00280-008-0695-9
13. JG Reves RJ Fragen HR Vinik DJ Greenblatt 1985 Midazolam: pharmacology and uses Anesthesiology 62 310 324 3156545 10.1097/00000542-198503000-00017 1:CAS:528:DyaL2MXhslymtrk%3D (Pubitemid 15101882)
14. WW Ten Bokkel Huinink J Sufliarsky WM Smit S Spanik M Wagnerova HW Hirte S Kaye AR Johri AM Oza 2009 Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study J Clin Oncol 27 3097 3103 19451434 10.1200/JCO.2008.20.4826 1:CAS:528:DC%2BD1MXhtFWitbzJ
15. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
16. L Wilson MA Jordan 1995 Microtubule dynamics: taking aim at a moving target Chem Biol 2 569 573 9383460 10.1016/1074-5521(95)90119-1 1:CAS:528:DyaK2MXos1Wjtbw%3D
17. R Yuan DA Flockhart JD Balian 1999 Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam J Clin Pharmacol 39 1109 1125 10579141 1:CAS:528: DC%2BD3cXivFWlsg%3D%3D (Pubitemid 30644013)
18. Zatloukal P, Mellemgaard A, Sanchez JM, Perry MC, Hamm JT, Van Meerbeeck J (2008) Activity of patupilone in advanced or metastatic non-small cell lung cancer (NSCLC): a phase II study. [abstract] Proceedings of the 33rd ESMO congress. Ann Oncol 19(Suppl 8):296P